



## ResApp to present at Gold Coast Investment Showcase

**Brisbane, Australia, 23 June 2022** – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that ResApp CEO and Managing Director, Tony Keating, will present at the Gold Coast Investment Showcase to be held at the JW Marriott Resort and Spa, Surfers Paradise today, Thursday 23<sup>rd</sup> of June 2022 at 3:15pm AEST.

The presentation will also be live-streamed via Zoom. The live-stream is free, and registration is available via this link:

<https://www.goldcoastinvestmentshowcase.com.au/livestreamingregistration.html>

###

### About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit [www.resapphealth.com.au](http://www.resapphealth.com.au).

### Contacts

Dr Tony Keating  
CEO and Managing Director  
+61 430 180 659  
[tony@resapphealth.com.au](mailto:tony@resapphealth.com.au)

Mr Brian Leedman  
Executive Director, Corporate Affairs  
+61 412 281 780  
[brian@resapphealth.com.au](mailto:brian@resapphealth.com.au)

*This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.*